Article

FDG-PET/CT: new horizons in anal cancer.

Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University Medical Center, Saint Louis, Missouri, USA.
Gastroentérologie Clinique et Biologique (impact factor: 0.8). 05/2009; 33(5):456-8. DOI:10.1016/j.gcb.2009.01.012 pp.456-8
Source: PubMed

ABSTRACT Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.

0 0
 · 
1 Bookmark
 · 
61 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Current treatment guidelines
 
defining sites
 
distant metastases
 
FDG-PET/CT
 
fluorodeoxyglucose positron emission tomography
 
human immunodeficiency virus
 
human papillomavirus
 
long-term clinical outcomes
 
lymph node status
 
metabolically active tumor
 
patients
 
pelvis
 
physical examination
 
Posttherapy FDG-PET/CT
 
primary tumor size
 
radiation therapy treatment planning
 
standard pretreatment workup
 
Traditional pretreatment evaluations
 
uncommon tumor
 

P W Grigsby